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Enterococcus spp bacteremia is associated with high mortality and the appearance of high-level gentamicin resistance (HLGR)
created additional challenges for the treatment of these infections. We evaluated the epidemiological and clinical characteristics
of patients with bacteremias caused by HLGR and non–HLGR Enterococcus faecalis isolates at a teaching hospital in the State
of São Paulo, Brazil. Patients with bacteremia due to E. faecalis diagnosed between January 1999 and December 2003 were
included in the study. We collected clinical, epidemiological, and microbiological data from medical records. Banked isolates
were typed using pulsed-field gel electrophoresis. We identified 145 cases of E. faecalis bacteremia: 66 (45.5%) were caused
by HLGR isolates and 79 (54.5%) by non–HLGR. In the univariate analysis, patients with HLGR infection were older, had higher
rates of bladder catheterization, and more often had treatment with cephalosporin, quinolone, and/or carbapenem compared
with patients with non–HLGR infection (P < 0.05). Multivariate analysis indicated that older age, hematological malignancy, and
previous use of vancomycin were independently associated with HLGR (P < 0.05). Mortality rates were not significantly different
among patients with HLGR (50%) and non–HLGR (43%) infections (P = 0.40). Of the 32 genotyped isolates, 16 were distributed
into 6 main electrophoresis patterns and 16 others had distinct patterns. E. faecalis bacteremia is associated with high mortality
and is frequently caused by HLGR isolates at this teaching hospital. The variability among genotyped isolates suggests that
endogenous infections, rather than patient-to-patient transmission of E. faecalis, are more common at this institution.
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Introduction
Enterococcus spp is the third most frequent cause of
hospital-acquired bacteremia, accounting for 8% of all
nosocomial bacteremias in the United States (1). High-
level gentamicin resistance (HLGR) has emerged among
Enterococcus spp over the last two decades, and is asso-
ciated with the loss of synergy between cell-active antibiot-
ics (e.g., vancomycin and penicillin, particularly ampicillin)
and most aminoglycosides (e.g., gentamicin, tobramycin,
amikacin, and kanamycin), thus posing additional treat-
ment challenges (2).
Enterococcal bacteremia is associated with high mor-
tality, which is even further increased when caused by
HLGR strains compared with those caused by non–HLGR
strains (3-5). In Brazil, clinical and epidemiological studies
of enterococcal infections have been less comprehensive,
with most studies focusing on vancomycin-resistant En-
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terococcus (VRE), which is still restricted to a few Brazilian
hospitals (6-8).
Since Enterococcus spp is the second most common
cause of Gram-positive blood stream infections in Brazil
and that approximately 76% of all enterococcal infections
are due to Enterococcus faecalis, we evaluated cases of
bacteremia caused by this organism at the teaching hospi-
tal of the Universidade Estadual de Campinas (Unicamp),
Campinas, São Paulo State (8). Our objective was to
characterize the epidemiological, clinical, and microbio-
logical features of bacteremias caused by HLGR and non–
HLGR E. faecalis isolated from January 1999 through
December 2003. This evaluation could help identify meas-
ures to reduce the frequency of these infections, especially
when caused by HLGR bacteria.
Patients and Methods
Hospital setting
The teaching hospital of Unicamp is a 403-bed, ter-
tiary-care hospital that serves an estimated population of 5
million people. During the study period, there were ap-
proximately 14,000 admissions per year.
Study population
Patients with E. faecalis bacteremia were identified
through a review of blood-culture records at the hospital
microbiology laboratory. In accordance with current guide-
lines, E. faecalis bacteremia was defined as at least one
positive blood culture for this pathogen (9). In patients with
multiple episodes of bacteremia, only the first episode was
considered for inclusion in this study.
Study design
We reviewed patient medical records using standard
forms and collected data on potential risk factors for en-
terococcal infections. These included epidemiological and
clinical information (age, gender, hospitalization ward, pri-
mary diagnosis, underlying chronic diseases, and severity
of disease) and microbiological data (monomicrobial or
polymicrobial etiology and antimicrobial susceptibility of E.
faecalis). The severity of disease was estimated using the
Charlson score (10). Invasive procedures prior to bacter-
emia onset, such as surgery, urinary bladder catheteriza-
tion, mechanical ventilation, central venous catheteriza-
tion, and administration of antimicrobials prior to the iden-
tification of E. faecalis, were also recorded.
Definitions
Community-acquired E. faecalis bacteremia was de-
fined as a positive blood culture drawn <72 h from patient
admission or evidence of infection at the time of admission.
Nosocomial E. faecalis bacteremia, conversely, was de-
fined as a positive blood culture drawn ≥72 h after admis-
sion and absence of any evidence of infection at admis-
sion.
Identification and antimicrobial susceptibility testing
Enterococcus species and antimicrobial susceptibility
were determined using the Gram-Positive Identification
Card® and Gram-Positive Susceptibility Card®, respective-
ly (bioMérieux Vitek®, Marcy l’Étoile, France). A minimum
inhibitory concentration of 500 µg/mL was used as the cut-
off value for HLGR according to manufacturer guidelines.
Genotyping
DNA was extracted as described previously (11). Puri-
fied DNA was digested with the restriction enzyme SmaI
and products were separated by pulsed-field gel electro-
phoresis (PFGE) on 1.0% agarose gels using CHEF-DRIII
(Bio-Rad Laboratories, USA). Pulse time was increased
from 5 to 35 s, at 6.0 V/cm for 20 h at 14°C. Gel images
were captured and analyzed using autoradiographic im-
ages from IS-1000 digital imaging system (Bio-Capt MW,
version 99, M&S Instruments Trading Inc., France). We
estimated the relationship among the isolates using the
Dice coefficient (Biogene software, Vilbert-Loumart,
France). Isolates with similarity <85% by PFGE were con-
sidered to be genetically unrelated, while similarity of
≥85% was considered evidence of isolates belonging to
the same PFGE subtype (12). PFGE profiles were identi-
fied by capital letters.
Statistical analysis
Univariate analysis was performed using logistic re-
gression, and the Fisher exact and Mann-Whitney tests,
when appropriate. Variables for which an association with
HLGR was suspected (i.e., P value ≤0.20) were included in
a multivariate stepwise logistic regression model. We con-
sidered the P value < 0.05 to be statistically significant.
Results
A total of 145 cases of bacteremia caused by E. faecalis
were identified: 66 (45.5%) were HLGR and 79 (54.5%)
non–HLGR. Cases of nosocomial bacteremia numbered
115 (80%). Polymicrobial bacteremia was present in 70
(48.3%) cases and Gram-negative bacilli were isolated in
42 (60%) of those.
Gender distribution was similar in patients with HLGR
and non–HLGR infections (Table 1). In addition, patients
with HLGR were older than patients without HLGR, median
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age of 48.5 years (range: 10–81 years) versus 38 years
(range: 1 day–80 years), respectively (P = 0.008). Length of
hospitalization prior to bacteremia diagnosis did not differ
significantly between patients with HLGR (14 days) and
non–HLGR (13 days) infection (P = 0.47). Among underly-
ing chronic diseases, only hematological malignancies
were significantly associated with HLGR bacteremia (P =
0.005; Table 1).
The association between any antimicrobial therapy
and the presence of HLGR bacteremia approached statis-
tical significance (P = 0.06). However, when each antimi-
crobial was evaluated individually, HLGR was associated
with previous use of quinolone [odds ratio (OR) = 2.79,
95% confidence interval (CI) = 1.19–6.53], carbapenem
[OR = 4.52, 95%CI = 1.19–17.20], and cephalosporin [OR
= 1.98, 95%CI = 1.02–3.84; Table 1].
Urinary catheterization was found to be associated
significantly with HLGR bacteremia (P = 0.02). We were
unable to show an association of other invasive proce-
dures and HLGR bacteremia (Table 1).
Multivariate stepwise logistic regression analysis
showed that age (at 10-year intervals; adjusted OR = 1.33,
95%CI = 1.13–1.57), hematological malignancies (adjusted
OR = 4.92, 95%CI = 1.82–13.27), and previous use of
vancomycin (adjusted OR = 3.93, 95%CI = 1.06–14.52)
were each associated independently with HLGR infection.
Of the 145 patients, 67 (46.2%) died during hospitaliza-
tion. Bacteremia by HLGR isolates did not influence pa-
tient outcome; 33 (50%) of 66 patients with HLGR bacter-
emia died versus 34 (43%) of 79 with non–HLGR bacter-
Table 1. Univariate analysis of factors associated with high-level gentamicin-resistant (HLGR)
and non–HLGR Enterococcus faecalis bacteremia.
Variables HLGR (N = 66) Non–HLGR (N = 79)  OR   95%CI
Gender (male) 34 (51.5%) 44 (55.7%) 1.18 0.61–2.28
Age
0–14 years 1 (1.5%) 24 (30.4%)
14–64 years 49 (74.3%) 40 (50.6%)
>65 16 (24.2%) 15 (19.0%)
For each 10 years 1.27 1.09–1.47
Charlson score, median (range) 2 (0–6) 2 (0–9)
At least 1 underlying diagnosisa 61 (92.4%) 67 (84.8%) 2.19 0.73–6.56
Hypertension 14 (21.2%) 14 (17.7%) 1.25 0.55–2.85
Solid malignancy 11 (16.7%) 14 (17.7%) 0.93 0.39–2.21
Hematological malignancy 18 (27.8%)* 7 (8.9%) 3.86 1.50–9.94
Chronic renal failure 11 (16.7%) 10 (12.6%) 1.38 0.55–3.49
Diabetes mellitus 10 (15.0%) 8 (10.1%) 1.59 0.59–4.28
Prior use of antimicrobials
Any antimicrobial 46 (70.0%) 43 (54.4%) 1.93 0.97–3.83
Aminoglycoside 7 (10.61%) 14 (17.7%) 0.55 0.21–1.46
Carbapenem 10 (15.1%)* 3 (3.8%) 4.52 1.19–17.2
Cephalosporin 37 (56.0%)* 31 (39.2%) 1.98 1.02–3.84
Metronidazol 19 (28.8%) 14 (17.7%) 1.88 0.86–4.12
Penicillins 5 (7.60%) 13 (16.5%) 0.42 0.14–1.24
Quinolone 19 (28.8%)* 10 (12.6%) 2.79 1.19–6.53
Vancomycin 9 (13.6%) 4 (5.0%) 2.96 0.87–10.1
Others 1 (1.5%) 5 (6.3%) 0.23 0.03–2.00
Hospital procedures
Central venous catheter 46 (69.7%) 51 (64.6%) 1.26 0.63–2.54
Urinary catheter 44 (66.7%)* 38 (48.1%) 2.16 1.10–4.24
Mechanical ventilation 22 (33.3%) 27 (34.2%) 0.96 0.48–1.92
Surgery 22 (33.3%) 25 (31.6%) 1.08 0.54–2.17
Polymicrobial bacteremia 36 (54.5%) 34 (43.0%) 1.59 0.82–3.07
Data are reported as number with percent in parentheses. aSome patients had more than one
underlying diagnosis. *P < 0.005 compared to non-HLGR bacteria (univariate logistic regression).
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emia (P = 0.40).
Evaluation of antimicrobial resistance revealed that 40
(27.6%) E. faecalis isolates had high-level resistance to
streptomycin alone, 84 (57.9%) had high-level resistance
to either gentamicin or streptomycin, and 22 (33.3%) had
high-level resistance to both gentamicin and streptomycin.
Resistance to ampicillin was present in 3% of isolates and
was not significantly associated with HLGR (P = 0.60).
Additionally, the prevalence of resistance to ciprofloxacin
was significantly higher among HLGR than non–HLGR
isolates (92.4 vs 11.4%, respectively; P < 0.001). Vanco-
mycin resistance was not detected in any isolate.
Only 32 (22%) E. faecalis isolates were available for
PFGE. We constructed a dendrogram based on PFGE
results (Figure 1). Sixteen isolates were grouped in six
main PFGE patterns. The remaining 16 isolates had dis-
tinct PFGE profiles. Molecular profiles D and F included
HLGR E. faecalis isolates only, while all isolates in group E
were non–HLGR. PFGE profiles A, B, and C were com-
prised of HLGR and non–HLGR E. faecalis isolates. Of the
six PFGE profiles with more than one isolate, profiles A, C,
D, and F had isolates collected from patients admitted to
hospital wards ≥30 feet apart.
Discussion
Enterococcus spp has gained importance over the last
years partially due to its increase in prevalence and the
emergence of multiresistant strains in the hospital setting.
The prevalence of HLGR enterococcal bacteremia has
been found to be between 7 and 63% in North American
hospitals (5,13,14). This wide variation might be explained
by differences in study designs, sources of specimens,
and species considered. Previous studies of antimicrobial
susceptibility of Enterococcus spp in Brazil, not focused on
E. faecalis and with samples from different sites (blood,
urine, and sputum), found the prevalence of HLGR to
range from 27 to 55% (6,7). In our study, the first to focus
on E. faecalis bacteremia in Brazil, 45% of cases were due
to HLGR isolates.
Figure 1. Dendrogram of pulsed-field gel electrophoresis profiles of 32 Enterococcus faecalis isolates (numbered isolates) and
American type culture collection (ATCC) E. faecalis reference strain.
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The ability of Enterococcus to survive in the environ-
ment facilitates the survival of multidrug-resistant strains,
creating more opportunities for person-to-person trans-
mission to occur. This attribute suggests that Enterococ-
cus and its resistance to antimicrobial drugs could con-
tinue to pose a challenge for both clinicians and hospital
epidemiologists. In addition, the concomitant isolation of
enterococci and other microorganisms in blood cultures
has been reported in 24–49% of cases (3,4,14,15). This
can make therapeutic decisions even more difficult and
potentially worsen prognosis. We observed a polymicro-
bial bacteremia prevalence of 48% with no significant
difference between HLGR and non–HLGR isolates. How-
ever, the association of gentamicin-resistant strains and
polymicrobial infections has not been conclusively estab-
lished in the literature (13-15).
Patients with HLGR infections were significantly older
than patients with non–HLGR infections. Previous studies,
however, have not shown this difference comparing HLGR
and non–HLGR E. faecalis infections (5,13,16). A low preva-
lence of HLGR, 4%, has been reported in a pediatric
hospital (17). We speculate that the use of antimicrobials
could be more judicious in pediatric patients, creating less
selective pressure on drug-resistant bacteria. Additionally,
the SENTRY Antimicrobial Surveillance Program has iden-
tified age-associated differences in pathogen prevalence
and antimicrobial susceptibility among organisms causing
bloodstream infections in North American hospitals (18).
This program found, for example, that bloodstream infec-
tions caused by VRE occurred more frequently in adults
than pediatric patients. It is unclear why age-related differ-
ences in antimicrobial susceptibilities occur.
In our study, hematological malignancies were the only
underlying disease or condition significantly associated
with higher rates of bacteremias caused by HLGR. Other
studies have shown association of HLGR infection with
chronic renal failure (16). We hypothesize that our results
may be related to the practice at our hospital of using
antimicrobial prophylaxis with quinolones among hemato-
logical patients, which might contribute to the selection of
resistant strains. Similarly, an association between HLGR
and resistance to ciprofloxacin among E. faecalis isolates
has been described in the UK and Ireland (19). The use of
glycopeptides, quinolones, carbapenems, and cepha-
losporins has also been associated with the emergence of
gentamicin resistance and selection of HLGR strains in the
past (5,16). We found an association between HLGR and
previous use of cephalosporin, quinolone, and carbapenen
in the univariate analysis. This underscores the need for
infection-control programs to promote judicious use of
antimicrobials to decrease selective pressure on E. faecalis.
Our data showed that high-level resistance to both
gentamicin and streptomycin was lower (22%) than other
studies (41–82%) (5,14). Resistance to both of these ami-
noglycosides limits the treatment options in terms of com-
bination therapy for severe enterococcal infections, such
as endocarditis and meningitis. Of note, recommendations
regarding the use of combination therapy for enterococcal
bacteremia have not been delineated with certainty in the
literature due to the absence of controlled trials to support
it. However, infectious disease specialists recommend
combination therapy for such infections, especially in criti-
cally ill patients (4).
The overall mortality among patients with enterococcal
bacteremia was 46.2%, which is consistent with previous
reports (30–68%) (3,4,15). Moreover, we found that mortal-
ity due to E. faecalis was similar regardless of the isolate’s
sensitivity to gentamicin, which is also consistent with the
results of other studies (5,13,14). The high mortality rates
observed in patients with enterococcal bacteremia may
reflect the severity of underlying illnesses. Unfortunately,
we were not able to determine the contribution of E. faecalis
infection alone on mortality because patients commonly
had other risk factors that could be associated with death,
e.g., polymicrobial infection and advanced age.
Molecular typing of Enterococcus isolates showed high
variability among isolates, even among HLGR isolates.
This molecular diversity suggests that isolates were se-
lected from endogenous intestinal flora, rather than a
result of patient-to-patient transmission. Similar findings
have been reported by others (11). Nonetheless, we found
a few E. faecalis isolates with similar PFGE patterns,
suggesting that patient-to-patient transmission might have
also occurred at our hospital. The finding of HLGR and
non–HLGR isolates with the same PFGE pattern can be
explained by the fact that PFGE is based on chromosomal
DNA; HLGR phenotype, on the other hand, is associated
with plasmids, which can be transferred independently
from chromosomal DNA.
Our study is subject to several limitations. First, due to
its retrospective design, it was not possible to use a more
accurate index of severity of illness, such as the acute
physiology and chronic health disease classification sys-
tem II (APACHE II), and control for it in our analysis.
Second, only a few of the isolates were available for
genotyping, which limited our ability to evaluate transmis-
sion patterns. Finally, we focused on cases occurring over
a four-year period, which may not be enough time for
changes in antibiotic susceptibility to occur.
This study is the first to highlight the clinical, epidemio-
logical, and microbiological characteristics of E. faecalis
bacteremia at a large tertiary teaching hospital in Brazil. In
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addition, our results emphasize the need for strategies to
improve infection-control practices, such as judicious use
of antibiotics and monitoring of antibiotic resistance among
hematologic patients. This could prevent further dissemi-
nation of HLGR, allow the monitoring of changes in entero-
coccal resistance patterns, and ultimately prevent the
spread of VRE at our institution, which is currently limited
to a few cases of colonization (20).
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